EU/3/14/1407

About

On 16 December 2014, orphan designation (EU/3/14/1407) was granted by the European Commission to Biodan Yelah S.L., Spain, for allogeneic adipose-derived adult mesenchymal stem cells contained in a fibrin-based bioengineered dermis for the treatment of epidermolysis bullosa.

Key facts

Active substance
Allogeneic adipose-derived adult mesenchymal stem cells contained in a fibrin-based bioengineered dermis
Disease / condition
Treatment of epidermolysis bullosa
Date of decision
16/12/2014
Outcome
Positive
Orphan decision number
EU/3/14/1407

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Biodan Yelah S.L.
Arbea Park 4 - 2º
Ave Fuencarral Km 3,8
28108 Alcobendas
Madrid
Spain
Tel. +34 671 926 572
E-mail: info@suriadan.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating